2-((4-(1-[ 11C]Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy) methyl)-quinoline (MP-10), a specific PDE10A inhibitor (IC 50 = 0.18 nM with 100-fold selectivity over other PDEs), was radiosynthesized by alkylation of the desmethyl precursor with [ 11C]CH 3I, ∼45% yield, >92% radiochemical purity, >370 GBq/μmol specific activity at end of bombardment (EOB). Evaluation in Sprague-Dawley rats revealed that [ 11C]MP-10 had highest brain accumulation in the PDE10A enriched-striatum, the 30 min striatum: cerebellum ratio reached 6.55. MicroPET studies of [ 11C]MP-10 in monkeys displayed selective uptake in striatum. However, a radiolabeled metabolite capable of penetrating the blood-brain-barrier may limit the clinical utility of [ 11C]MP-10 as a PDE10A PET tracer.

Original languageEnglish
Pages (from-to)1666-1673
Number of pages8
JournalBioorganic and Medicinal Chemistry
Issue number5
StatePublished - Mar 1 2011


  • Carbon-11
  • Huntington's disease
  • MP-10
  • PDE10A
  • PET imaging


Dive into the research topics of 'Radiosynthesis and in vivo evaluation of [ 11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain'. Together they form a unique fingerprint.

Cite this